Dexmedetomidine HCL Injection + Midazolam Injection
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mechanically Ventilated and Intubated Subjects
Conditions
Mechanically Ventilated and Intubated Subjects
Trial Timeline
Mar 1, 2005 → Aug 1, 2007
NCT ID
NCT00216190About Dexmedetomidine HCL Injection + Midazolam Injection
Dexmedetomidine HCL Injection + Midazolam Injection is a approved stage product being developed by Pfizer for Mechanically Ventilated and Intubated Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT00216190. Target conditions include Mechanically Ventilated and Intubated Subjects.
What happened to similar drugs?
0 of 1 similar drugs in Mechanically Ventilated and Intubated Subjects were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00216190 | Approved | Completed |
Competing Products
2 competing products in Mechanically Ventilated and Intubated Subjects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dexmedetomidine, midazolam; fentanyl | Pfizer | Phase 2 | 35 |
| Dexmedetomidine | Orion Corporation | Phase 3 | 37 |